JREISSATI Pancreatic Centre | Epworth

APRISE study eligibility criteria

The **A**ustralian **P**ancreatic high-**RI**sk **S**cr**E**ening (APRISE) Study is a national study that will screen high-risk individuals with a familial and/or genetic predisposition to pancreatic cancer.

Who is eligible?

Individuals aged ≥18 and ≤90 years old with no history of pancreatic cancer, **AND** meeting ANY of the following criteria:

Familial Pancreatic Cancer Group 1

- ≥2 relatives with pancreatic cancer, on same side of family, where the 2 affected are first degree related to each other **AND**
- ≥ 1 affected is first degree related to subject **AND**
- ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family at diagnosis.

Pathogenic variants

- *BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2*, or *EPCAM* pathogenic or likely pathogenic variant **AND**
- 1 first or second degree relative with pancreatic cancer **AND**
- ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family.

Peutz-Jegher Syndrome

- Peutz-Jegher Syndrome with *STK11* pathogenic or likely pathogenic variant **AND**
- ≥35 years of age.

Familial Pancreatic Cancer Group 2

- ≥2 affected first degree relatives with pancreatic cancer **AND**
- ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family.

Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM)

- Familial Atypical Multiple Mole Melanoma (FAMMM) with pathogenic or likely pathogenic *CDKN2A* variant **AND**
- ≥40 years of age.

Hereditary pancreatitis

- Hereditary pancreatitis with *PRSS1* pathogenic or likely pathogenic variant **AND**
- history of pancreatitis **AND**
- ≥40 years of age, or 20 years after onset of pancreatitis (whichever is earlier).

Exclusion criteria:

- Clinically unfit to undergo surveillance by EUS or MRI.
- Previously diagnosed with or treated for pancreatic cancer.

For more information on participating sites across Australia or to refer a patient, contact us at 0418 370 684 or visit our website by scanning the QR code.

This study is proudly funded by Epworth HealthCare, Pankind: Pancreatic Cancer Australia, the Viridian Foundation, and the Victorian Government through the Victorian Cancer Agency.

NP4058_JPC_0725